TI
AMLX icon

Trexquant Investment’s Amylyx Pharmaceuticals AMLX Stock Holding History

Trexquant Investment’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,112
Closed -$581K – 1737
2025
Q4 		$581K Sell
48,112
-174,764
-78% -$2.37M 0.01% 1308
2025
Q3 		$3.03M Buy
+222,876
New +$2.1M 0.03% 740
2024
Q1 		– Sell
-265,046
Closed -$3.9M – 1411
2023
Q4 		$3.9M Buy
+265,046
New +$4.06M 0.09% 327

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Trexquant Investment's AMLX Position: Q1 2026 in Review

Trexquant Investment sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 48,112 shares — an estimated $581K sold.

Trexquant Investment first reported a position in AMLX in Q4 2023 and held it in 3 quarters. The position peaked at $3.9M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Trexquant Investment reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Trexquant Investment sold 48,112 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $581K.
  • Trexquant Investment first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Trexquant Investment's Amylyx Pharmaceuticals position peaked at $3.9M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.